Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

The round was led by the US venture capital (VC) firm General Catalyst Partners with participation from compatriot VC Greylock Partners in addition to strategic investors. Manas will use the proceeds ...

Head of solution value at One2Treat, Émilie Barré shares her journey to date with Outsourcing-Pharma. Could you give us an overview of your work? I have recently been promoted to head of solution ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...

From Novo Holding’s purchase of Catalent to BMS’s Karuna acquisition, here are 10 of the most significant M&A moments last year Compared to the previous years, 2024 has been a relatively slow year for ...

Australian contract development and manufacturing organizations (CDMOs), BioCina and NovaCina, have merged in a move to pool their biologic and small molecule production expertise and infrastructure.